These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 9403274)

  • 1. Phase I clinical trial of cefditoren pivoxil (ME1207). Tolerance in healthy volunteers.
    Li JT; Hou F; Lu H; Li TY; Li H
    Drugs Exp Clin Res; 1997; 23(3-4):131-8. PubMed ID: 9403274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers.
    Li JT; Hou F; Lu H; Li TY; Li H
    Drugs Exp Clin Res; 1997; 23(5-6):145-50. PubMed ID: 9515223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study.
    Sádaba B; Azanza JR; Quetglas EG; Campanero MA; Honorato J; Coronel P; Gimeno M
    Rev Esp Quimioter; 2007 Mar; 20(1):51-60. PubMed ID: 17530036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of cefditoren pivoxil in treatment of respiratory infections, a clinical study].
    Li JT; Gao L; Xue F; Hao FL; Wang Q; Cai BQ; Gan CL; Liu YN; Yu BX; He LX; Hu BJ; Chen XH; Zheng JC; Yu YS; Lu FF; Liang DR; Cai YN; Kang J; Kong LF; Xiao ZL; Zheng JP; Liu J; Yang WX; Zhou J
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):391-4. PubMed ID: 12820915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial.
    Poachanukoon O; Kitcharoensakkul M
    Clin Ther; 2008 Oct; 30(10):1870-9. PubMed ID: 19014842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
    Mant T; Jurcevic S; Szakacs C; Adams L; Boland J; Hewitt LA
    Clin Ther; 2008 Jan; 30(1):131-42. PubMed ID: 18343249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers.
    Barbanoj MJ; Urbano G; Antonijoan R; Ballester MR; Valle M
    Neuropsychobiology; 2007; 55(3-4):203-12. PubMed ID: 17878744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
    Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of foods on the pharmacokinetics and clinical efficacy of quazepam.
    Kim Y; Morikawa M; Ohsawa H; Kou M; Ishida E; Igarashi J; Kajimoto T; Danno T; Nakata M; Yokoyama T; Tokuyama A; Nakamura Y; Kishimoto T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Oct; 23(5):205-10. PubMed ID: 14653226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
    Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
    Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses.
    Algorta J; Pena MA; Maraschiello C; Alvarez-González A; Maruhn D; Windisch M; Mucke HA
    Methods Find Exp Clin Pharmacol; 2008 Mar; 30(2):141-7. PubMed ID: 18560630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
    Asai F; Jakubowski JA; Naganuma H; Brandt JT; Matsushima N; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):209-17. PubMed ID: 16769598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold.
    Eccles R; Jawad MS; Jawad SS; Angello JT; Druce HM
    Am J Rhinol; 2005; 19(1):25-31. PubMed ID: 15794071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.